| Centerstone Of Tennesse Inc. | |
|
7011 A C Skinner Pkwy Jacksonville FL 32256-6954 | |
| (904) 431-3500 | |
| (904) 431-3501 |
| Full Name | Centerstone Of Tennesse Inc. |
|---|---|
| Speciality | Clinic/Center |
| Location | 7011 A C Skinner Pkwy, Jacksonville, Florida |
| Authorized Official Name and Position | Karen Lynette Keene (SECURITY OFFICER, IT TECHNOLOGY SUP) |
| Authorized Official Contact | 6154636523 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Centerstone Of Tennesse Inc. Po Box 197520 Nashville TN 37219-7520 Ph: (615) 463-6669 | Centerstone Of Tennesse Inc. 7011 A C Skinner Pkwy Jacksonville FL 32256-6954 Ph: (904) 431-3500 |
| NPI Number | 1144836982 |
|---|---|
| Provider Enumeration Date | 09/17/2020 |
| Last Update Date | 09/17/2020 |
| Certification Date | 09/17/2020 |
| Medicare PECOS PAC ID | 9739088113 |
|---|---|
| Medicare Enrollment ID | O20210304000841 |
News Archive
Charles H. Hennekens, M.D., DrPH, the first Sir Richard Doll Research Professor of Medicine in the Charles E. Schmidt College of Medicine at Florida Atlantic University, has published a commentary for clinicians in this week's issue of The Journal of the American Medical Association.
Neoprobe Corporation (OTCBB:NEOP), a diversified developer of innovative oncology surgical and diagnostic products, today announced consolidated results for the second quarter of 2009 and for the six-month period ended June 30, 2009.
A study at UCLA's Jonsson Comprehensive Cancer Center has found that head and neck cancer patients receiving radiation as part of their treatment were less likely to need a feeding tube or suffer unwanted side effects such as worsening of diet or narrowing of the throat passage if they performed a set of prescribed swallowing exercises - called a "swallow preservation protocol" - during therapy.
Navidea Biopharmaceuticals, Inc., a specialty pharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that data from its Phase 3 clinical study investigating 99m-Tc-Tilmanocept in oral and squamous cell cancers (SCC) were presented as a poster presentation at the 65th Annual Cancer Symposium of the Society of Surgical Oncology (SSO) meeting held in Orlando, Florida, March 21-24, 2012.
› Verified 9 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1144836982 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 261QM0801X | Clinic/center - Mental Health (including Community Mental Health Center) | (* (Not Available)) | Primary |
| Provider Name | Nicole M Wells-cimmino |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1013269133 PECOS PAC ID: 9830505577 Enrollment ID: I20210304001225 |
News Archive
Charles H. Hennekens, M.D., DrPH, the first Sir Richard Doll Research Professor of Medicine in the Charles E. Schmidt College of Medicine at Florida Atlantic University, has published a commentary for clinicians in this week's issue of The Journal of the American Medical Association.
Neoprobe Corporation (OTCBB:NEOP), a diversified developer of innovative oncology surgical and diagnostic products, today announced consolidated results for the second quarter of 2009 and for the six-month period ended June 30, 2009.
A study at UCLA's Jonsson Comprehensive Cancer Center has found that head and neck cancer patients receiving radiation as part of their treatment were less likely to need a feeding tube or suffer unwanted side effects such as worsening of diet or narrowing of the throat passage if they performed a set of prescribed swallowing exercises - called a "swallow preservation protocol" - during therapy.
Navidea Biopharmaceuticals, Inc., a specialty pharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that data from its Phase 3 clinical study investigating 99m-Tc-Tilmanocept in oral and squamous cell cancers (SCC) were presented as a poster presentation at the 65th Annual Cancer Symposium of the Society of Surgical Oncology (SSO) meeting held in Orlando, Florida, March 21-24, 2012.
› Verified 9 days ago
| Provider Name | Natalie Janine Byram |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1841897287 PECOS PAC ID: 1951772607 Enrollment ID: I20230117002679 |
News Archive
Charles H. Hennekens, M.D., DrPH, the first Sir Richard Doll Research Professor of Medicine in the Charles E. Schmidt College of Medicine at Florida Atlantic University, has published a commentary for clinicians in this week's issue of The Journal of the American Medical Association.
Neoprobe Corporation (OTCBB:NEOP), a diversified developer of innovative oncology surgical and diagnostic products, today announced consolidated results for the second quarter of 2009 and for the six-month period ended June 30, 2009.
A study at UCLA's Jonsson Comprehensive Cancer Center has found that head and neck cancer patients receiving radiation as part of their treatment were less likely to need a feeding tube or suffer unwanted side effects such as worsening of diet or narrowing of the throat passage if they performed a set of prescribed swallowing exercises - called a "swallow preservation protocol" - during therapy.
Navidea Biopharmaceuticals, Inc., a specialty pharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that data from its Phase 3 clinical study investigating 99m-Tc-Tilmanocept in oral and squamous cell cancers (SCC) were presented as a poster presentation at the 65th Annual Cancer Symposium of the Society of Surgical Oncology (SSO) meeting held in Orlando, Florida, March 21-24, 2012.
› Verified 9 days ago
| Provider Name | Alexandra Katherine Field |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1730525247 PECOS PAC ID: 7012375918 Enrollment ID: I20230626001712 |
News Archive
Charles H. Hennekens, M.D., DrPH, the first Sir Richard Doll Research Professor of Medicine in the Charles E. Schmidt College of Medicine at Florida Atlantic University, has published a commentary for clinicians in this week's issue of The Journal of the American Medical Association.
Neoprobe Corporation (OTCBB:NEOP), a diversified developer of innovative oncology surgical and diagnostic products, today announced consolidated results for the second quarter of 2009 and for the six-month period ended June 30, 2009.
A study at UCLA's Jonsson Comprehensive Cancer Center has found that head and neck cancer patients receiving radiation as part of their treatment were less likely to need a feeding tube or suffer unwanted side effects such as worsening of diet or narrowing of the throat passage if they performed a set of prescribed swallowing exercises - called a "swallow preservation protocol" - during therapy.
Navidea Biopharmaceuticals, Inc., a specialty pharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that data from its Phase 3 clinical study investigating 99m-Tc-Tilmanocept in oral and squamous cell cancers (SCC) were presented as a poster presentation at the 65th Annual Cancer Symposium of the Society of Surgical Oncology (SSO) meeting held in Orlando, Florida, March 21-24, 2012.
› Verified 9 days ago
| Provider Name | Deanna Marie Iovino |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1265988604 PECOS PAC ID: 4284092065 Enrollment ID: I20230627001291 |
News Archive
Charles H. Hennekens, M.D., DrPH, the first Sir Richard Doll Research Professor of Medicine in the Charles E. Schmidt College of Medicine at Florida Atlantic University, has published a commentary for clinicians in this week's issue of The Journal of the American Medical Association.
Neoprobe Corporation (OTCBB:NEOP), a diversified developer of innovative oncology surgical and diagnostic products, today announced consolidated results for the second quarter of 2009 and for the six-month period ended June 30, 2009.
A study at UCLA's Jonsson Comprehensive Cancer Center has found that head and neck cancer patients receiving radiation as part of their treatment were less likely to need a feeding tube or suffer unwanted side effects such as worsening of diet or narrowing of the throat passage if they performed a set of prescribed swallowing exercises - called a "swallow preservation protocol" - during therapy.
Navidea Biopharmaceuticals, Inc., a specialty pharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that data from its Phase 3 clinical study investigating 99m-Tc-Tilmanocept in oral and squamous cell cancers (SCC) were presented as a poster presentation at the 65th Annual Cancer Symposium of the Society of Surgical Oncology (SSO) meeting held in Orlando, Florida, March 21-24, 2012.
› Verified 9 days ago
| Provider Name | Princes Mccarther |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1265058952 PECOS PAC ID: 1153780739 Enrollment ID: I20230629001275 |
News Archive
Charles H. Hennekens, M.D., DrPH, the first Sir Richard Doll Research Professor of Medicine in the Charles E. Schmidt College of Medicine at Florida Atlantic University, has published a commentary for clinicians in this week's issue of The Journal of the American Medical Association.
Neoprobe Corporation (OTCBB:NEOP), a diversified developer of innovative oncology surgical and diagnostic products, today announced consolidated results for the second quarter of 2009 and for the six-month period ended June 30, 2009.
A study at UCLA's Jonsson Comprehensive Cancer Center has found that head and neck cancer patients receiving radiation as part of their treatment were less likely to need a feeding tube or suffer unwanted side effects such as worsening of diet or narrowing of the throat passage if they performed a set of prescribed swallowing exercises - called a "swallow preservation protocol" - during therapy.
Navidea Biopharmaceuticals, Inc., a specialty pharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that data from its Phase 3 clinical study investigating 99m-Tc-Tilmanocept in oral and squamous cell cancers (SCC) were presented as a poster presentation at the 65th Annual Cancer Symposium of the Society of Surgical Oncology (SSO) meeting held in Orlando, Florida, March 21-24, 2012.
› Verified 9 days ago
| Provider Name | Zoe Panizzi |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1255769220 PECOS PAC ID: 1759519705 Enrollment ID: I20230811001027 |
News Archive
Charles H. Hennekens, M.D., DrPH, the first Sir Richard Doll Research Professor of Medicine in the Charles E. Schmidt College of Medicine at Florida Atlantic University, has published a commentary for clinicians in this week's issue of The Journal of the American Medical Association.
Neoprobe Corporation (OTCBB:NEOP), a diversified developer of innovative oncology surgical and diagnostic products, today announced consolidated results for the second quarter of 2009 and for the six-month period ended June 30, 2009.
A study at UCLA's Jonsson Comprehensive Cancer Center has found that head and neck cancer patients receiving radiation as part of their treatment were less likely to need a feeding tube or suffer unwanted side effects such as worsening of diet or narrowing of the throat passage if they performed a set of prescribed swallowing exercises - called a "swallow preservation protocol" - during therapy.
Navidea Biopharmaceuticals, Inc., a specialty pharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that data from its Phase 3 clinical study investigating 99m-Tc-Tilmanocept in oral and squamous cell cancers (SCC) were presented as a poster presentation at the 65th Annual Cancer Symposium of the Society of Surgical Oncology (SSO) meeting held in Orlando, Florida, March 21-24, 2012.
› Verified 9 days ago
| Provider Name | Kelly M Capel |
|---|---|
| Provider Type | Practitioner - Mental Health Counselor |
| Provider Identifiers | NPI Number: 1437780616 PECOS PAC ID: 5092167536 Enrollment ID: I20240119001862 |
News Archive
Charles H. Hennekens, M.D., DrPH, the first Sir Richard Doll Research Professor of Medicine in the Charles E. Schmidt College of Medicine at Florida Atlantic University, has published a commentary for clinicians in this week's issue of The Journal of the American Medical Association.
Neoprobe Corporation (OTCBB:NEOP), a diversified developer of innovative oncology surgical and diagnostic products, today announced consolidated results for the second quarter of 2009 and for the six-month period ended June 30, 2009.
A study at UCLA's Jonsson Comprehensive Cancer Center has found that head and neck cancer patients receiving radiation as part of their treatment were less likely to need a feeding tube or suffer unwanted side effects such as worsening of diet or narrowing of the throat passage if they performed a set of prescribed swallowing exercises - called a "swallow preservation protocol" - during therapy.
Navidea Biopharmaceuticals, Inc., a specialty pharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that data from its Phase 3 clinical study investigating 99m-Tc-Tilmanocept in oral and squamous cell cancers (SCC) were presented as a poster presentation at the 65th Annual Cancer Symposium of the Society of Surgical Oncology (SSO) meeting held in Orlando, Florida, March 21-24, 2012.
› Verified 9 days ago
| Provider Name | Jodie L Bielman |
|---|---|
| Provider Type | Practitioner - Mental Health Counselor |
| Provider Identifiers | NPI Number: 1114454527 PECOS PAC ID: 9133571474 Enrollment ID: I20240123000380 |
News Archive
Charles H. Hennekens, M.D., DrPH, the first Sir Richard Doll Research Professor of Medicine in the Charles E. Schmidt College of Medicine at Florida Atlantic University, has published a commentary for clinicians in this week's issue of The Journal of the American Medical Association.
Neoprobe Corporation (OTCBB:NEOP), a diversified developer of innovative oncology surgical and diagnostic products, today announced consolidated results for the second quarter of 2009 and for the six-month period ended June 30, 2009.
A study at UCLA's Jonsson Comprehensive Cancer Center has found that head and neck cancer patients receiving radiation as part of their treatment were less likely to need a feeding tube or suffer unwanted side effects such as worsening of diet or narrowing of the throat passage if they performed a set of prescribed swallowing exercises - called a "swallow preservation protocol" - during therapy.
Navidea Biopharmaceuticals, Inc., a specialty pharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that data from its Phase 3 clinical study investigating 99m-Tc-Tilmanocept in oral and squamous cell cancers (SCC) were presented as a poster presentation at the 65th Annual Cancer Symposium of the Society of Surgical Oncology (SSO) meeting held in Orlando, Florida, March 21-24, 2012.
› Verified 9 days ago
| Provider Name | Ashley Carter |
|---|---|
| Provider Type | Practitioner - Other (non-physician) |
| Provider Identifiers | NPI Number: 1598162059 PECOS PAC ID: 6002268430 Enrollment ID: I20240227004601 |
News Archive
Charles H. Hennekens, M.D., DrPH, the first Sir Richard Doll Research Professor of Medicine in the Charles E. Schmidt College of Medicine at Florida Atlantic University, has published a commentary for clinicians in this week's issue of The Journal of the American Medical Association.
Neoprobe Corporation (OTCBB:NEOP), a diversified developer of innovative oncology surgical and diagnostic products, today announced consolidated results for the second quarter of 2009 and for the six-month period ended June 30, 2009.
A study at UCLA's Jonsson Comprehensive Cancer Center has found that head and neck cancer patients receiving radiation as part of their treatment were less likely to need a feeding tube or suffer unwanted side effects such as worsening of diet or narrowing of the throat passage if they performed a set of prescribed swallowing exercises - called a "swallow preservation protocol" - during therapy.
Navidea Biopharmaceuticals, Inc., a specialty pharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that data from its Phase 3 clinical study investigating 99m-Tc-Tilmanocept in oral and squamous cell cancers (SCC) were presented as a poster presentation at the 65th Annual Cancer Symposium of the Society of Surgical Oncology (SSO) meeting held in Orlando, Florida, March 21-24, 2012.
› Verified 9 days ago
News Archive
Charles H. Hennekens, M.D., DrPH, the first Sir Richard Doll Research Professor of Medicine in the Charles E. Schmidt College of Medicine at Florida Atlantic University, has published a commentary for clinicians in this week's issue of The Journal of the American Medical Association.
Neoprobe Corporation (OTCBB:NEOP), a diversified developer of innovative oncology surgical and diagnostic products, today announced consolidated results for the second quarter of 2009 and for the six-month period ended June 30, 2009.
A study at UCLA's Jonsson Comprehensive Cancer Center has found that head and neck cancer patients receiving radiation as part of their treatment were less likely to need a feeding tube or suffer unwanted side effects such as worsening of diet or narrowing of the throat passage if they performed a set of prescribed swallowing exercises - called a "swallow preservation protocol" - during therapy.
Navidea Biopharmaceuticals, Inc., a specialty pharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that data from its Phase 3 clinical study investigating 99m-Tc-Tilmanocept in oral and squamous cell cancers (SCC) were presented as a poster presentation at the 65th Annual Cancer Symposium of the Society of Surgical Oncology (SSO) meeting held in Orlando, Florida, March 21-24, 2012.
› Verified 9 days ago
Mark Dearing,lcsw Inc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 12412 San Jose Blvd Ste 401, Jacksonville, FL 32223 Phone: 904-348-0343 | |
Reconnect Consulting Inc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 3955 Riverside Ave, Jacksonville, FL 32205 Phone: 904-483-3843 | |
South Rehabilitation Center, Inc. Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 580 Ellis Rd S, Suite 118, Jacksonville, FL 32254 Phone: 904-423-0017 Fax: 904-683-8169 | |
Mtb Therapist, Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 6034 Chester Ave, Jacksonville, FL 32217 Phone: 904-323-2019 | |
Mc Medical Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 12100 Lem Turner Rd Unit 100, Jacksonville, FL 32218 Phone: 904-764-2855 Fax: 904-764-2670 | |
Westland Therapy Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 6196 Lake Gray Blvd, Jacksonville, FL 32244 Phone: 718-483-5093 | |
Accessible Home Health Care Of South Central Massachusetts Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 4131 University Blvd S Ste 10, Jacksonville, FL 32216 Phone: 508-769-2707 |